Compare TG Therapeutics Inc (TGTX) vs Twilio Inc (TWLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Twilio Inc — how do they compare? TG Therapeutics Inc trades at $54.77 (market cap $8.53B), while Twilio Inc trades at $226.41 (market cap $34.69B). The key difference: Twilio Inc is far larger — about 4.1× TG Therapeutics Inc's market cap. Which is the better fit depends on your goals.
| TGTX | TWLO | |
|---|---|---|
Market Cap | $8.53B | $34.69B |
Sector | Health | Technology |
52-Week High | $59.06 | $255.95 |
52-Week Low | $26.94 | $100.09 |
Enterprise Value | $8.74B | $33.10B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Twilio (TWLO) trades at $225.89, down 3.04% on the day, showing strong fundamental momentum with three consecutive quarterly earnings beats and accelerating revenue growth from $3.8B in 2022 to $5.1B in 2025. The company has achieved profitability with net income turning positive at $33.83M in 2025 after years of losses, while technical indicators show neutral signals with support at $222 and resistance at $230.
TWLO presents a compelling growth story with 76.9% analyst buy ratings and a $267.25 consensus price target representing 18% upside. Key risks include premium valuation metrics (P/E 31.2, EV/EBITDA 66.3) and potential execution challenges in the competitive communications software space, though AI-driven product expansion provides growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Twilio Inc
Twilio Inc. is a cloud-based communication platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces, or APIs, and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
Read more on TWLO →
